Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant

Blood

Volumn 91, Issue 10, 1998, Pages 3671-3680

  Alyea, Edwin P ^a,b   Soiffer, Robert J ^a   Canning, Christine ^a   Neuberg, Donna ^a   Schlossman, Robert ^a   Pickett, Christopher ^a   Collins, Heather ^a   Wang, Yulan ^a   Anderson, Kenneth C ^a   Ritz, Jerome ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; LEUKEMIA CELL; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE SUBPOPULATION;

EID: 20244374668     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.10.3671     Document Type: Article

References (51)

1. Kolb HJ, Mittermuller J, Clem C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
2. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
3. Cullis J, Jiang Y, Schwarer A, Hughes T, Barren A, Goldman J: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation (correspondence). Blood 79: 1379, 1992
4. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 12:125, 1993
5. Leber B, Walker IR, Rodriguez A, McBride JA, Carter R, Brain MC: Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant 12:405, 1993
6. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
7. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 82:2273, 1993
8. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041, 1995
9. Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R, Goodman S, Wolff S, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin J, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997
10. Korngold R, Sprent J: T cell subsets and graft-versus-host disease. Transplantation 44:335, 1987
11. Renkonen R, Hayry P: Cellular infiltrates in the target organs associated with acute graft-versus-host disease. Bone Marrow Transplant 2:333, 1987
12. Weisdorf SA, Roy J, Snover D, Platt JL, Weisdorf DJ: Inflammatory cells in graft-versus-host disease on the rectum: Immunopathologic analysis. Bone Marrow Transplant 7:297, 1991
13. Perrault C, Jutras J, Roy D, Filep J, Brochu S: Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease. J Clin Invest 98:622, 1996
14. Diamond D, Chang K, Jenkins K, Forman S: Immunohistochemical analysis of T cell phenotypes in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 59:1436, 1995
15. Dietrich PY, Caignard A, Lim A, Chung V, Pico JL, Pannetier C, Kourilsky P, Hercend T, Even J, Triebel F: In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood 84:2815, 1994
16. Gaschet J, Trevino MA, Cherel M, Vivien R, Garcia-Sahuquillo A, Hallet MM, Bonneville M, Harrousseau JL, Bragado R, Milpied N, Vie H: HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease. Blood 87:2345, 1996
17. Truitt RL, LeFever AV, Shih AV, Jeske JM, Martin TM: Graft-Versus-Host Disease. Immunology, Pathophysiology and Treatment. New York, NY, Marcel Dekker, 1990
18. Truitt RL, Atasoylu AA: Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8:51, 1991
19. Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283, 1992
20. Fowler D, Breglio J, Nagel G, Eckhaus M, Gress R: Allospecific CD8+ Tcl and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 157:4811, 1996
21. Fowler D, Breglio J, Nagel G, Hirose C, Gress R: Allospecific CD4 + , Th1/Th2 and CD8 + ,Tcl/Tc2 populations in murine GVL: Type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 2:118, 1996
22. Korngold R, Leighton C, Manser T: Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58:278, 1994
23. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155, 1990
24. Korngold R: Biology of graft-vs.-host disease. Am J Pediatr Hematol Oncol 15:18, 1993
25. Soiffer RJ, Gonin R, Murray C, Robertson MJ, Cochran K, Chartier S, Cameron C, Daley J, Levine H, Nadler LM, Ritz J: Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood 82:2216, 1993
26. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:418, 1990
27. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch M, Isacescu V, Reichert T, Champlin R: Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 57:82, 1994
28. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ: Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68:770, 1986
29. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
30. Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R, Miller KB, Rudders RA, Freeman A, Blake K, Coral F, Nadler LM, Ritz J: Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191, 1992
31. Rohatiner A, Gelber R, Schlossman SF, Ritz J: Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. Transplantation 42:73, 1986
32. Przepiorka D, Weisdorf D, Martin P, Klingeman H-G, Beatty P, Hows J, Thomas E: Consensus conference on acute GVHD grading. Bone Marrow Transplantation 15:825, 1995
33. Kwok S, Hiushi R: Avoidings false positives with PCR. Nature 339:237, 1989
34. Delage R, Soiffer RJ, Dear K, Ritz J: Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 78:2759, 1991
35. Pichert G, Roy D, Gonin R, Alyea E, Belanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C, Soiffer R, Ritz J: Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 13:1704, 1995
36. Rosner B: Fundamentals of Biostatistics (ed 3). Boston, MA, PWS-Kent, 1990
37. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
38. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA: Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1:665, 1984
39. Soiffer R, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman R, Stone R, Murray C, Freeman A. Marcus K, Mauch P, Nadler L, Ritz J: CD6 depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 89:3039, 1997
40. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337, 1995
41. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377, 1994
42. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195, 1996
43. Lokhorst H, Schattenberg A, Cornelissen J, Thomas L, Verdonck L: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206, 1997
44. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
45. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828, 1989
46. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, O'Reilly R: Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response? Bone Marrow Transplant 15:591, 1995
47. Claret E, Alyea E, Orsini E, Pickett C, Collins H, Wang Y, Neuberg D, Soiffer R, Ritz J: Characterization of T cell repertoire in patients with graft-versus-leukemia following donor lymphocyte infusion. J Clin Invest 100:855, 1997
48. Keil F, Haas O, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix H: Donor leukocyte infusion for leukemic relapse after allogeneic bone marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 89:3113, 1997
49. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522, 1996
50. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH: Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 96:877, 1995
51. Goulmy E: Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157:125, 1997